Correction: High-throughput screening of FDA-approved drugs identifies colchicine as a potential therapeutic agent for atypical teratoid/rhabdoid tumors (AT/RTs)

Abstract

Correction: High-throughput screening of FDAapproved drugs identifies colchicine as a potential therapeutic agent for atypical teratoid/rhabdoid tumors (AT/RTs) Phongthon Kanjanasirirat,abc Kedchin Jearawuttanakul,c Sawinee Seemakhan,c Suparerk Borwornpinyo,cd Patompon Wongtrakoongate,ef Suradej Hongengcg and Sitthivut Charoensutthivarakul*acf Correction for ‘High-throughput screening of FDA-approved drugs identifies colchicine as a potential therapeutic agent for atypical teratoid/rhabdoid tumors (AT/RTs)’ by Phongthon Kanjanasirirat et al., RSC Adv., 2025, 15, 12331–12341, https://doi.org/10.1039/D5RA01341K. The authors regret the omission of Tanawadee Khumpanied from the Acknowledgements. The correct Acknowledgements are as shown here. This research was partially supported by the Ramathibodi Foundation and Thailand Center of Excellence for Life Sciences (TCELS), and also by the Faculty of Science, Mahidol University via the Reinventing University Project. The authors would like to thank Dr Witchuda Saengsawang, Dr Jiraporn Panmanee and Dr Sujira Mukda for discussions and Ms Tanawadee Khumpanied for preliminary data collection. The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.